Q3 2025 Management View CEO Joshua Riggs highlighted that Insight Molecular Diagnostics is nearing a transformative milestone, stating, "In 2026, with the expected FDA authorization of GraftAssureDx, ...

The review also calls for embedding diagnostics within the One Health framework, which integrates human, animal, and ...

Given the success of the Research Topic ‘Diversity and Molecular Diagnostics of Fungi and Oomycetes in Plants’ Volume I and the rapidly evolving subject ...

The Point-of-Care Molecular Diagnostics Market is experiencing robust expansion driven by rising demand for rapid, accurate, ...

AI brings its own validation challenges. Unlike static assays, machine learning algorithms evolve as they ingest new data, ...

Nucleic acid testing (NAT) identifies specific pathogen genetic material (DNA or RNA), enabling early and precise diagnosis ...

Allied Market Research published a report, titled, "Molecular Spectroscopy Market by Technology (UV Visible Spectroscopy, ...

Analysts are estimating that Insight Molecular will report an earnings per share (EPS) of $-0.24. Anticipation surrounds Insight Molecular's announcement, with investors hoping to hear about both ...

Analysts are estimating that Co-Diagnostics will report an earnings per share (EPS) of $-0.19. Anticipation surrounds ...

Labroots is excited to host the 16th Annual Clinical Diagnostics & Research Virtual Event Series on November 12, 2025. This premier online event unites clinicians, lab professionals, and researchers ...

Insight Molecular Diagnostics Inc. ((IMDX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...